ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CEL Celadon Pharmaceuticals Plc

82.50
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Celadon Pharmaceuticals Investors - CEL

Celadon Pharmaceuticals Investors - CEL

Share Name Share Symbol Market Stock Type
Celadon Pharmaceuticals Plc CEL London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 82.50 08:00:00
Open Price Low Price High Price Close Price Previous Close
82.50 82.50 82.50 82.50
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 16/11/2023 07:38 by ahhh luke warm
Let's see if that adds more to the 135mlnMC. Jak, probably spot on with the shorting MM investor. What's your thoughts around John Gunn and GIS?
Posted at 16/11/2023 07:31 by ahhh luke warm
Financing unsecured CLNs at 10% interest. The last line is a red flag to this sort of set up. Mr Short came over all holy and clean and crisp but now associated with John Gunn financing. Tut, tut!At this stage it is anticipated that the Convertible Loan Notes will be issued at par with a 5 year term and will be unsecured. The notes are expected to carry a coupon of 10 per cent. per annum and to be convertible at the option of the investor after 2 years, or to be mandatorily converted into ordinary shares of 1 pence each ("Ordinary Shares") on a qualifying financing to be determined or change of control of the Company.
Posted at 16/11/2023 07:24 by ahhh luke warm
Jak, never a good sign unless it's for him where a John Gunn company appear in association; ie: GISFrom the raise RNS:The Company is also pleased to announce the appointment of Global Investment Strategy UK Limited as Joint Broker to the Company. Canaccord Genuity Limited will remain as NOMAD and a Broker to the Company.Future Convertible Loan NotesIn addition to the Fundraise above and following investor interest, the Company is seeking to raise further funding moving forward through the issuance of Convertible Loan Notes ("CLN Financing"). The Company has already received expressions of interest from potential investors to subscribe for the CLN Financing.
Posted at 13/10/2023 09:07 by jaknife
Who are these supposed "serious investors"? I assumed that it was the market maker that took up the placing after having gone short into the market for the previous six months!

There are no "serious investors" investing into Celadone. It's a loss-making, cash-burning spin machine and has net assets of just £3m. Yet the market cap is £77m!

People are paying £77m to buy £3m of assets, that's like paying £25 to buy a used £1 coin!
Posted at 13/10/2023 07:25 by czar
Serious investors just paid 125p when the morons were selling it at 115p, who is smarter, who knows more? I'm following the intelligent investors money and adding at 125p.
Posted at 16/3/2023 10:01 by czar
There clearly are very few private investors involved in CEL, several are using this thread to promote other stocks but none of these have the Home Office Licence. The truth is only a handful of companies worldwide can supply medical-grade cannabis to the pharmaceutical industry, this is an extremely valuable Company IMHO. Celadon will almost certainly receive a take over approach, its a question of WHEN not IF. The big question is at what level a bid will come in at and what would the management accept? GW Pharma gives a great clue as to the sort of number we can expect.

" -- Receipt of updated Home Office licence enables Celadon to commence the commercial supply of its GMP pharmaceutical cannabis product

-- GMP registration is understood to be the first such registration of a UK pharmaceutical facility for high THC cannabis active pharmaceutical ingredient ("API") since the legalisation of medical cannabis in 2018

-- GMP registration and a Home Office licence are required in order to sell high-THC medicinal cannabis in the UK

-- Celadon becomes one of a small number of companies globally with the capability to produce an EU-GMP grade high-THC cannabinoid API"
Posted at 10/8/2011 09:24 by chaka
Caparo Energy Limited

("Caparo Energy" or the "Company")

Caparo Energy closes second tranche of Mezzanine

Further orders placed with Suzlon

Directorate changes

Notice of EGM

Closed Second Tranche of Mezzanine:

The Board of Directors of Caparo Energy (the "Board") is pleased to announce that Caparo Energy (India) Limited ("CEIL"), the Company's wholly owned subsidiary, has closed a second tranche of mezzanine funding. This second tranche of mezzanine financing, which is for a 4 year term, of Rs. 1,500m (US$33.5m) is being provided by the Infrastructure Development Finance Company Limited ("IDFC").

As stated in the Company's previous announcement of 20 June 2011, the terms of both tranches of mezzanine financing entail no equity dilution for Caparo Energy's existing shareholders. The Board believes that this will result in enhanced equity returns for investors. The Company expects to repurchase/buy-back both tranches of mezzanine from internal cash flows and the issue of senior debt instruments, bonds or other debt refinancing, within three to five years.

The Board believes that securing these two tranches of financing, totalling Rs 5,000 (US$112m), is a significant step forward for the business and anticipates that this additional funding, along with the Company's existing resources, would enable the Company to develop approximately 700 MW of wind projects.

Purchase orders for 260 MW placed with Suzlon

Since our previous announcement, CEIL has placed specific purchase orders with Suzlon Energy Limited ("Suzlon") for a further 260 MW of wind projects for delivery by March 2012. When combined with the 100 MW ordered in February 2011, CEIL's total purchase orders have grown to 360 MW, of which 52 MW have already been commissioned, with the balance expected to be commissioned in stages by March 2012. The Company will release further updates of orders being placed for delivery by March 2012 in due course.

The new purchase orders for 260 MW cover five individual projects located in the states of Maharashtra, Gujarat, Karnataka and Rajasthan. All of these sites have wind data using a met mast measured at different heights for an average period of over four years and are fully permitted.

The Company has selected these sites based on detailed analysis and independent wind studies completed by internationally recognised firms in this field, and the Board is confident that these projects represent some of the best sites being commissioned in India over the next two years and that the Plant Load Factors ("PLF") for these sites are very attractive.

Following the placing of these orders, which are ahead of the schedule previously announced, the Board anticipates that by March 2012 the Company will have a total of 500 MW of fully operational projects connected to the grid and generating cash flow. Additionally, the Board expects to achieve the full 1 GW of project orders with Suzlon by March 2013.

Management Team of CEIL

CEIL has been building its management team and would like to report that it has identified and recruited certain key personnel to further execute the Company's strategy:

R. Ramakrishnan has been appointed as President of CEIL. Prior to this appointment, he was CEO/Managing Director at GMR Industries (GMR Group is a diversified infrastructure group in India with interests in power, airports and roads) for four years before becoming Group Corporate Head of its Renewable Energy business. Previously, he was the Chief Executive of Sanmar Group and, prior to that, was with the Murugappa Group for 20 years where he worked in Sales & Marketing, International Business Development, Product Management, Manufacturing & Technical services.

CEIL has also made a number of hires in various departments across the company including wind resources, project planning and execution, finance, legal and operations and maintenance, as it continues to look towards the Company's progressive growth for the future.

Directorate changes

The Company would also like to report changes in the composition of the Board:

Angad Paul, CEO of the Caparo Group, is stepping down from his current role as Non-Executive Chairman of the Company and will continue as a Non-Executive Director. Accordingly, Ravi Kailas has been appointed Chairman of the Company, in addition to his current role as CEO of the Company.

In addition, Charles Wilkinson, Independent Non-Executive Director of the Company based in Guernsey, will not be standing for re-election at the forthcoming AGM.

In light of these developments, the Company intends to appoint two additional independent Non Executive Directors to the Board in due course.

Notice of EGM

The Board announces that a circular containing a notice of Extraordinary General Meeting ("EGM"), to be convened for 5 September 2011, at 10 a.m at Anson Place, Mill Court, La Charroterie, St Peter Port, Guernsey, GY1 1EJ, Channel Islands, is today being sent to shareholders. The purpose of the EGM is to seek shareholder approval to update the relevant Board authorities to issue shares and dis-apply pre-emption rights and to change the name of the Company from Caparo Energy Limited to Mytrah Energy Limited.

The notice of EGM and form of proxy, together with an explanatory covering letter from the Chairman and Chief Executive Officer, is being posted to shareholders today and will shortly be made available on the Company's website at www.caparoenergy.com.

Ravi Kailas, Caparo Energy's Chairman and Chief Executive Officer, commented:

"The closing of the second tranche of mezzanine financing in a timely manner puts our company in a position to fund over 700 MW of wind projects without any dilution to existing shareholders. We are also pleased with the strengthening of our management team with people who have a proven track record in the industry. By placing 360 MW of orders with Suzlon for delivery by March 2012, the Company demonstrates again its ability to build utility scale wind power projects with an unprecedented efficiency.

"As the Company's transformative growth continues, its identity has also evolved. Accordingly, the Company is proposing to change it's name to Mytrah Energy Limited and we are excited by the Company's prospects of trading under this new identity. The Board would like to re-iterate its gratitude to have begun as Caparo Energy and would like to thank the Caparo Group for their on-going support to the Company."

Further information on the Company can be found at www.caparoenergy.com.
Posted at 03/9/2009 11:18 by verger
I am a veteran of RTD & CEL, and now they've both gone. Profits from them have more than covered many other disastrous investments! I have some shares in RENE (Reneuron) a stem cell research company showing promise, although we have been clobbered recently with a massive share placing with major investors at 3p. Nevertheless, it is slowly climbing. Could be useless, but there again...
I have some shares in AHT (Ashtead); you may wish to check it out. And I have just a few in XAR (Xaar), printer ink and all that; has plummeted from £3+, but is slowly recovering.
Posted at 28/6/2009 14:32 by dpeach
From Investors Chronicle :

Celsis pushes profits higher

Created: 26 June 2009 Written by: Jonas Crosland

Celsis International delivered a decent performance, thanks to another solid result from its Rapid Detection division which tests pharmaceutical company products for contamination. Turnover there rose 9.2 per cent to $23.7m (£14.5m).

However, turnover fell 13 per cent to $10.7m at IVT, Celsis' unit that supplies human and animal cells to drug developers for the purposes of carrying out early-stage safety tests on new drugs. Business levels declined following consolidation within the pharmaceutical industry and a general squeeze on research and development budgets as a result of the economic downturn.

Meanwhile, sales at the Analytical Services division, which provides outsourced laboratory testing services to pharmaceutical and consumer product companies, fell 4.7 per cent to $18.1m - although business picked up in the second half after falling 9.2 per cent in the first half. And following a strategic review, Celsis has decided to close the loss making Development Services division, which provided very early-stage and pre-clinical drug development laboratory services. Ongoing losses and closure related costs totalled $2.4m.

Celsis continues to run a tight ship, though, and reduced operating expenses by 9.7 per cent to $23.5m. Moreover, cash flow from continuing operations rose from $12.9m to $13.7m and, while the gross margin did edge slightly lower, it still stands at an impressive 69.8 per cent.

CELSIS INTERNATIONAL (CEL)
ORD PRICE: 182p MARKET VALUE: £39.8m
TOUCH: 179-186p 12-MONTH HIGH: 200p LOW: 129p
DIVIDEND YIELD: nil PE RATIO: 7
NET ASSET VALUE: 251c* NET CASH: $4.6m


Year to 31 Mar Turnover ($m) Pre-tax profit ($m) Earnings per share (¢) Dividend per share (¢)
2005 30.4 6.20 35.7 5.10
2006 33.1 7.20 20.8 nil
2007 47.4 8.70 26.8 nil
2008 52.9 10.5 32.8 nil
2009 52.5 12.8 41.9 nil
% change -1 +22 +28 -
Ex-div: -

Payment: -

*Includes intangible assets of $32.3m, or 147¢ a share £1 = $1.631



Click here for a guide to the terms used in IC results tables

For more analysis of company results as they're released, go to www.investorschronicle.co.uk/results


--------------------------------------------------------------------------------

IC VIEW:
GoodValueCelsis has cut costs and improved cash flow, while demand for its rapid detection services remains robust. True, there has been a slowdown in companies spending on research, but Celsis is well placed to take advantage of any improvement. Good value.

Last IC view: Buy, 144p, 17 November 2008.
Posted at 12/2/2009 09:42 by davidosh
The nil dividend has always been my complaint and I did raise the subject at the last Agm....In most defensive plays there will be a steady dividend return and if this is only seen as a growth play you need growth to excite investors with their cash. When there are so many on very low ratings that can be difficult.

I still like the company and its ability to weather the downturn and the cash backing rather than debt worries. However management need to show they can take action on the Analytical Division and also keep investors happy with buybacks or dividends or the share price will probably drift back. That of course may not worry them directly if planning a buyout or they wish to buy shares but investors in these markets want good secure dividends or a confident growth pattern and CEL is falling in between it seems. That is not to say the share price is expensive and long term will no doubt be fine.

Your Recent History

Delayed Upgrade Clock